Watchlist Price Alert

Arcus Biosciences Inc. (RCUS)

NYSE: RCUS · Real-Time Price · USD

8.91

-0.60 (-6.31%)

At close: May 30, 2025, 3:59 PM

9.26

3.87%

After-hours: May 30, 2025, 05:53 PM EDT

-6.31% (1D)

Bid	8.6
Market Cap	943.96M
Revenue (ttm)	141M
Net Income (ttm)	-391M
EPS (ttm)	-4.23
PE Ratio (ttm)	-2.11
Forward PE	-2.16
Analyst	Buy

Ask	9.26
Volume	1,149,982
Avg. Volume (20D)	1,151,354
Open	9.38
Previous Close	9.51
Day's Range	8.55 - 9.24
52-Week Range	6.50 - 18.98
Beta	0.87

About RCUS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol RCUS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for RCUS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

-1.35%

Arcus Biosciences shares are trading lower after t... Unlock content with Pro Subscription

3 months ago

-16.34%

Arcus Biosciences shares are trading lower after the company announced a $150 million stock offering.

News

5 days ago · businesswire.com

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

3 weeks ago · seekingalpha.com

Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript

Arcus Biosciences, Inc. (NYSE:RCUS ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Pia Eaves - VP, IR Terry Rosen - CEO Richard Markus - CMO Jennifer Jarrett - COO Bob G...

3 weeks ago · zacks.com

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $0.05 per share a year ago.

1 month ago · businesswire.com

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient...

2 months ago · seekingalpha.com

Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts

Arcus Biosciences presents a high-risk speculation with significant upcoming catalysts, despite recent stock declines and Gilead's exit from the ARC-10 trial. Gilead's continued investment and board p...